Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

207 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Gender and myocardial salvage after reperfusion treatment in acute myocardial infarction.
Mehilli J, Ndrepepa G, Kastrati A, Nekolla SG, Markwardt C, Bollwein H, Pache J, Martinoff S, Dirschinger J, Schwaiger M, Schömig A. Mehilli J, et al. Among authors: pache j. J Am Coll Cardiol. 2005 Mar 15;45(6):828-31. doi: 10.1016/j.jacc.2004.11.054. J Am Coll Cardiol. 2005. PMID: 15766814 Free article. Clinical Trial.
Sex and effect of abciximab in patients with acute coronary syndromes treated with percutaneous coronary interventions: results from Intracoronary Stenting and Antithrombotic Regimen: Rapid Early Action for Coronary Treatment 2 trial.
Mehilli J, Ndrepepa G, Kastrati A, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Kufner S, Dirschinger J, Berger PB, Schömig A. Mehilli J, et al. Among authors: pache j. Am Heart J. 2007 Jul;154(1):158.e1-7. doi: 10.1016/j.ahj.2007.03.050. Am Heart J. 2007. PMID: 17584569 Clinical Trial.
One-year clinical outcomes with abciximab vs. placebo in patients with non-ST-segment elevation acute coronary syndromes undergoing percutaneous coronary intervention after pre-treatment with clopidogrel: results of the ISAR-REACT 2 randomized trial.
Ndrepepa G, Kastrati A, Mehilli J, Neumann FJ, ten Berg J, Bruskina O, Dotzer F, Seyfarth M, Pache J, Dirschinger J, Berger PB, Schömig A. Ndrepepa G, et al. Among authors: pache j. Eur Heart J. 2008 Feb;29(4):455-61. doi: 10.1093/eurheartj/ehm562. Epub 2007 Dec 23. Eur Heart J. 2008. PMID: 18158289 Clinical Trial.
Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A, Neumann FJ, Mehilli J, Byrne RA, Iijima R, Büttner HJ, Khattab AA, Schulz S, Blankenship JC, Pache J, Minners J, Seyfarth M, Graf I, Skelding KA, Dirschinger J, Richardt G, Berger PB, Schömig A; ISAR-REACT 3 Trial Investigators. Kastrati A, et al. Among authors: pache j. N Engl J Med. 2008 Aug 14;359(7):688-96. doi: 10.1056/NEJMoa0802944. N Engl J Med. 2008. PMID: 18703471 Free article. Clinical Trial.
Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Mehilli J, Kastrati A, Schulz S, Früngel S, Nekolla SG, Moshage W, Dotzer F, Huber K, Pache J, Dirschinger J, Seyfarth M, Martinoff S, Schwaiger M, Schömig A; Bavarian Reperfusion Alternatives Evaluation-3 (BRAVE-3) Study Investigators. Mehilli J, et al. Among authors: pache j. Circulation. 2009 Apr 14;119(14):1933-40. doi: 10.1161/CIRCULATIONAHA.108.818617. Epub 2009 Mar 30. Circulation. 2009. PMID: 19332467 Clinical Trial.
Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
Mehilli J, Kastrati A, Byrne RA, Bruskina O, Iijima R, Schulz S, Pache J, Seyfarth M, Massberg S, Laugwitz KL, Dirschinger J, Schömig A; LEFT-MAIN Intracoronary Stenting and Angiographic Results: Drug-Eluting Stents for Unprotected Coronary Left Main Lesions Study Investigators. Mehilli J, et al. Among authors: pache j. J Am Coll Cardiol. 2009 May 12;53(19):1760-8. doi: 10.1016/j.jacc.2009.01.035. J Am Coll Cardiol. 2009. PMID: 19422982 Free article. Clinical Trial.
207 results